Early onset drug-induced hypersensitivity syndrome with lymphopenia, hepatitis, and normal eosinophils induced by BRAF/MEK inhibitor after immune checkpoint inhibitor therapy

Buhle, Anna; Johnson, Nathan A.; Grider, Douglas J.; Phillips, Mariana A

doi:10.5070/d328157062

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, further exploration of the CRC treatment is needed. 104 , 105 The IMblaze370 test showed that the combination of atezolizumab and cobimetinib had an effective rate of 8%. Compared to the single-drug group of atezolizumab and regorafenib, the OS for the combination of atezolizumab and cobimetinib was not significantly different, and the incidence of grade 3–4 AEs increased significantly to 64%.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Li¹,

Xu²

2023

IJGM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body's autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/ microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.

show abstract

Section: Introductionmentioning

confidence: 99%